Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Correspondence] Rifampicin in treating S aureus bacteraemia

The deduction that severely ill patients benefit from combination therapy might be tempting, but evidence supporting such an intensified treatment approach is controversial. This was once again shown by Guy E Thwaites and colleagues (Feb 17, p 668),1 who are to be commended for completing the ARREST trial, investigating possible benefits of adjunctive rifampicin in Staphylococcus aureus bacteraemia. The trial findings did not show a significant difference between the rifampicin and placebo groups concerning the composite primary endpoint (bacteriologically confirmed treatment failure or recurrence or all-cause death at week 12).